Oncology is the branch of study of medicine that deals with the prevention, diagnosis, and treatment of cancer. Sterile injectables are widely used in the treatment of cancer for increased biological effects. Injectable drug delivery is the mode of introduction of a drug directly into a patient’s bloodstream. Since it has to be injected directly into the bloodstream, it needs to be sterile. Sterile injectable drugs are usually manufacture in form of liquid and they permit the transport of drugs directly into the body blood circulation, sometimes they may be formulated to transport the drug to a specific part of the body. The manufacturing of sterile injectable drugs in a complex process and incurs high initial investment and operating costs. Hence, a small number of players hold major share of the global sterile injectables market.
The global oncology sterile injectable drugs market is expected to grow at a rapid pace due to increase in chronic diseases across the world, especially oncology disorders such as cancer and others; rise in investment by drug manufacturers in the development of new anti-cancer drugs; short timelines for approval of new drug for the treatment of cancer, and faster approvals by the FDA are the key factors boosting demand for oncology sterile injectables globally. However, stringent rules and regulations in related facilities and equipment involved in the manufacture of oncological sterile injectable drugs, and high level of quality and care required in the production, storage, packaging, and distribution of oncological sterile injectable are likely to hamper the growth of the market.
The global oncology sterile injectable drugs market can be segmented based on type, end-user, and region. In terms of type, the global market can be divided into small molecules and large molecules. Small molecule is the most attractive segment of the market due to increase in development and adoption of small molecules in chronic diseases such as cancer. Based on end-user, the global oncology sterile injectable drugs market can be classified into hospitals, ambulatory surgical center, specialty clinics, and others.
Geographically, the global oncology sterile injectable drugs market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Each region is sub-divided into specific countries such as the U.S., Canada, the U.K., Germany, Brazil, China, India, and GCC Countries. North America dominated the global oncology sterile injectable drugs market because of increase in geriatric population, rise in incidence of chronic and autoimmune diseases, and surge in demand for innovative medical technology in the U.S. According to the National Institute of Cancer, in 2016, around 1,685,210 new cancer cases are likely to be diagnosed in the U.S. and 595,690 patients will succumb to the disease. Asia Pacific is considered to be the most attractive market during the forecast period due to rise in health awareness and demand for advanced medical technology.
Key players operating in the global oncology sterile injectable drugs market are Amgen, Inc., Baxter International Genentech, Inc., Novo Nordisk A/S, Johnson & Johnson, Sanofi S.A., Pfizer, Inc., GlaxoSmithKline plc, AstraZeneca, and Merck & Co., Inc., among others. Major players have adopted various growth strategies such as collaborations, agreements, partnerships, and new product launches to gain competitive advantage in the market.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.